Louisiana State Employees Retirement System bought a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 11,700 shares of the company’s stock, valued at approximately $223,000.
Several other institutional investors have also recently added to or reduced their stakes in ITOS. BlackRock Inc. raised its holdings in iTeos Therapeutics by 106.5% during the first quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock worth $107,203,000 after purchasing an additional 1,718,085 shares in the last quarter. State Street Corp lifted its position in iTeos Therapeutics by 124.3% in the first quarter. State Street Corp now owns 1,711,891 shares of the company’s stock valued at $55,089,000 after acquiring an additional 948,540 shares during the last quarter. Vanguard Group Inc. boosted its stake in iTeos Therapeutics by 39.1% in the first quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock valued at $47,499,000 after acquiring an additional 415,232 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 146.7% during the second quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company’s stock worth $11,522,000 after purchasing an additional 332,625 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of iTeos Therapeutics by 276.9% in the 2nd quarter. AQR Capital Management LLC now owns 445,110 shares of the company’s stock valued at $9,169,000 after purchasing an additional 327,025 shares during the last quarter.
iTeos Therapeutics Stock Down 1.3 %
NASDAQ:ITOS opened at $18.95 on Friday. The company has a market capitalization of $674.15 million, a PE ratio of 2.75 and a beta of 1.38. iTeos Therapeutics, Inc. has a 52-week low of $16.21 and a 52-week high of $41.00. The stock’s 50 day moving average price is $19.70 and its 200 day moving average price is $21.09.
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Deere, Catepillar, PACCAR, Machinery Stocks You Need to Know
- 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
- Optimism About Global Demand For Metals Boosts BHP, Other Miners
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.